about
Stage B: what is the evidence for treatment of asymptomatic left ventricular dysfunction?Use of an argatroban-based purge solution in a percutaneous ventricular assist device.Building a sustainable system of leadership development for pharmacy: report of the 2008-09 Argus Commission.Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease.A practical guide for the treatment of symptomatic heart failure with reduced ejection fraction (HFrEF).Stage A: can heart failure be prevented?Comparison of intravenous and oral magnesium replacement in hospitalized patients with cardiovascular disease.Clinical update on the management of atrial fibrillation.Acute decompensated heart failure: evolving literature and implications for future practice.Distinguishing anemia and iron deficiency of heart failure: signal for severity of disease or unmet therapeutic need?Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure.Polypharmacy in heart failure: drugs to use and avoid.Medication management of cardiac allograft vasculopathy after heart transplantation.The impact of drug shortages on patients with cardiovascular disease: causes, consequences, and a call to action.Beliefs and behaviors of professionally engaged pharmacists.Safe and Effective Use of Pharmacologic and Device Therapy for Peripartum Cardiomyopathy.No filter: A characterization of #pharmacist posts on Instagram.Putting class IIb recommendations to the test: the influence of unwitnessed and Non-VT/VF arrests on resource consumption and outcomes in therapeutic hypothermia and targeted temperature management.Pharmacologic Considerations in the Management of Patients Receiving Left Ventricular Percutaneous Mechanical Circulatory Support.From Pilot to Practice: A Trainee-Integrated Pharmacy Practice Model in Cardiology.Efficacy and Safety of Intravenous Chlorothiazide versus Oral Metolazone in Patients with Acute Decompensated Heart Failure and Loop Diuretic Resistance.Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients.Diltiazem versus metoprolol for rate control in atrial fibrillation with rapid ventricular response in the emergency department.Key articles and guidelines in the management of pulmonary arterial hypertension: 2011 update.Impact of video technology on efficiency of pharmacist-provided anticoagulation counseling and patient comprehension.Observation of Patients Transitioned to an Oral Loop Diuretic Before Discharge and Risk of Readmission for Acute Decompensated Heart Failure.Effects of an accelerated intravenous iron regimen in hospitalized patients with advanced heart failure and iron deficiency.Diuretic Resistance in Acute Decompensated Heart Failure: A Challenging Clinical Conundrum.Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart AssociationBuilding the business model for medication therapy management servicesContinuous quality improvement in all phases of practice mandatory for preventing medication errorsPharmacy practice around the worldHealth care reform and the role of the pharmacistLessons in Bridge-Building: A Multidisciplinary Approach to Heart Failure CareInteractive Web-based regional journal club for postgraduate year 2 pharmacy residents in cardiologyAntithromboembolic Strategies for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary InterventionSurvey of Anticoagulation Practices with the Impella Percutaneous Ventricular Assist Device at High-Volume Centers
P50
Q26853063-2AEE6202-110A-4151-9483-97067560D114Q33441307-237B779D-6FF5-4D33-930D-2C9B31FC313BQ33694124-4A5A463C-57BC-4AE7-8126-AE4679F8601BQ34474985-352C7ECD-EF2D-43CB-88F7-925C351803B6Q35139947-9CE8EC8A-4E9D-4FBF-A977-BC55A169FE1FQ35139955-CC779313-35DC-4B76-AECF-15FE5B959807Q38023805-3D30527A-258C-41EB-A75B-472875717BB1Q38095871-DA821800-435E-49FC-BEED-2C27653918ADQ38161451-8A4F957D-7B96-4097-B934-CEEC008490C0Q38199991-078B0C6C-7422-4EAA-B83A-405037D5C4BBQ38248810-5C0364A3-A162-423F-B852-064C3D09F195Q38248811-D55D5DCD-9546-4356-9206-7211BD9A83B9Q38502794-3F784CE0-262E-4E53-8277-256D7A223A0BQ38834578-752ED79E-64A4-42D1-B838-F4C83A6C7102Q38852618-8CEE2BA9-D5C1-41D1-AE4F-01DB5523F098Q38884855-333C44FF-8385-4CC7-92D4-319F0B47D818Q38924572-17B51B1A-F278-47DD-B464-587D4F85D394Q39192760-545CC343-5629-4205-9439-EDF2E209D765Q39457136-64CC2A5C-F597-40D9-B80A-318DE75A736AQ40111792-F6438DFD-F2EF-4524-B0AF-DE0DC88B3825Q40388134-047B1AA3-3B4A-474F-B255-B8DF4FFA8DF8Q50940254-3DFE26DC-FD3B-4900-8DE7-B30F0B1CECA8Q51026935-33F8EA0E-DFB7-4846-97B0-1A8A271BC311Q51613389-6F73DBC1-98AF-409A-A797-F63C23B9DAAAQ53228938-DC0D9A89-1181-47C3-A15A-29EE76599F8BQ53475647-DF8C7072-BDB5-4555-B742-A940CDC04F9CQ53646838-16F79C12-932A-46E4-A6FE-9232F6915C9AQ53728211-EA75280E-14B6-4B76-B7BE-D087E31484E6Q56386358-1BA4D60B-864E-4387-956A-CF78E381CC05Q80485875-1A3E3A3A-0A91-4639-B57A-B26ED9B214FCQ80579563-682CDA83-34FB-4241-869F-E82EB3460590Q83303254-7A541C6C-7A12-4C6C-A603-DD25892BA8A2Q83833113-39CC2949-255A-45B6-A3C6-BFE599F5C945Q87896209-7905898A-BF0D-489B-898D-B8B7162B4C4CQ88165903-075E976E-AF03-44F8-BB22-05B99139B299Q89145725-CC55AED2-1F82-4E1E-9B59-BDA3334BC90BQ91475370-3D74639F-F907-43C0-9B9B-70C8A63BAC4F
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Brent N Reed
@ast
Brent N Reed
@en
Brent N Reed
@es
Brent N Reed
@nl
Brent N Reed
@sl
type
label
Brent N Reed
@ast
Brent N Reed
@en
Brent N Reed
@es
Brent N Reed
@nl
Brent N Reed
@sl
prefLabel
Brent N Reed
@ast
Brent N Reed
@en
Brent N Reed
@es
Brent N Reed
@nl
Brent N Reed
@sl
P106
P21
P31
P496
0000-0002-3867-070X